7675-04-9

Basic information

• Product Name: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one
• Synonyms: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one;5,6-dihydrothieno[2,3-b]thiopyran-4-one;5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one（WS204342）
• CAS NO: 7675-04-9
• Molecular Formula: C7H6OS2
• Molecular Weight: 170.255
• Mol File: 7675-04-9.mol

Chemical Properties

• Boiling Point: 308.283°C at 760 mmHg
• Flash Point: 140.245°C
• Appearance: /
• Density: 1.398
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.663
• CAS DataBase Reference: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one(7675-04-9)
• EPA Substance Registry System: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one(7675-04-9)

Safety Data

• Hazardous Substances Data: 7675-04-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one serves as a fundamental building block in organic synthesis, facilitating the creation of a diverse array of chemical compounds with various applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one is utilized as a key intermediate in the development of new drugs. Its unique structure allows for the exploration of its potential as a therapeutic agent across different medical fields.
Used in Medicinal Chemistry:
5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one is employed as a target molecule in medicinal chemistry, where its biological activities and drug-like properties are investigated and harnessed for the advancement of pharmaceuticals.
Used in Drug Development:
5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one is leveraged in drug development processes, where its properties are optimized and fine-tuned to enhance its efficacy and safety as a potential therapeutic agent.
Used in Bioactive Molecule Development:
5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-one is also used in the development of bioactive molecules, where its unique structure contributes to the discovery of new molecules with specific biological functions and applications.

InChI:InChI=1/C7H6OS2/c8-6-2-4-10-7-5(6)1-3-9-7/h1,3H,2,4H2

Upstream product

• 7675-03-8 3-thiophen-2-ylsulfanyl-propionyl chloride 
• 7675-01-6 3-(thien-2-ylthio)propionic acid 
• 21339-38-8 2H-thieno<2,3-b>thiopyran 

Downstream Products

• 105951-35-7 5,6-dihydro-4H-4-oxothieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide 
• 105951-31-3 5,6-dihydro-4H-4-oxothieno[2,3-b]thiopyran-2-sulfonamide 
• 105951-30-2 5,6-dihydro-4H-4-hydroxythieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide 

Relevant articles and documents

Discovery of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors

Small molecule tyrosine kinase inhibitors (TKIs) targeting at epidermal growth factor receptor (EGFR) in recent years have made great progress in the treatment of advanced non-small cell cancer (NSCLC). Although as the first-line treatment for sensitizing EGFR mutation-positive metastatic NSCLC, gefitinib has also behaved quite a lot of side effect and EGFR tolerance. Herein, a novel series of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives were designed and synthesized, and screened for their inhibitory activity on the EGFR high-expressing human lung adenocarcinoma cell line A549 and human large cell lung cancer cell line NCI-H460 by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay. The calculated IC50 values were reported. Compound 8h demonstrated the most potent inhibitory activity (IC50 = 9.57 ± 2.20 μmol L–1 for A549 and IC50 = 13.04 ± 1.21 μmol L–1 for NCI-H460), comparable to the positive-control gefitinib (IC50 = 8.58 ± 1.65 μmol L–1 for A549 and IC50 = 18.66 ± 5.01 μmol L–1 for NCI-H460). Conclusively, 7-bromo- 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the EGFR–TKIs were discovered, and could be used as potential leading compounds for further research.

Trimethylamine and application of trimethylamine

The invention belongs to the field of medicine technology, and relates to a trimethylamine and apreparation method thereof and an application as the epidermal growth factor receptor tyrosine kinase inhibitor. The compounds, a prodrugs of the compounds, a pharmaceutically active metabolites and the pharmaceutically acceptable salts have the structure of formula (I) : R may be independently selectedfrom the group consisting of hydrogen, C1-C6 alkyl; R', R'' are independently selected from the group consisting of hydrogen, C1-C6 alkyl, substituted or unsubstituted phenyl, wherein the substituentis C1-C4 alkyl, C1-C4 alkoxy, halogen, halogenated C1-C4 alkyl, halogenated C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, wherein the substituent is dimethylamino, morpholinyl, methoxyphenoxy, methoxyphenyl; R', and R'', together with a nitrogen atom to which they are attached, form a morpholinyl or a cycloaliphatic radical. The formula is shown in the formula.

1 - (4 - Hydroxy imine base thiophen and [2, 3 - b] thiapyran formyl) piperazine compound and use thereof (by machine translation)

The invention belongs to the field of medical technology, relates to 1 - (4 - hydroxy imine base thiophen and [2, 3 - b] thiapyran formyl) piperazine compound and its application. The 1 - (4 - hydroxy imine base thiophen and [2, 3 - b] thiapyran formyl) piperazine compound comprises the following structure, wherein R is selected from hydrogen, halogen, C1 - C4 alkyl, C1 - C4 alkoxy, halogenated C1 - C4 alkyl, halogenated C1 - C4 alkoxy. The invention the 1 - (4 - hydroxy imine base thiophen and [2, 3 - b] thiapyran formyl) piperazine compound, a stereoisomer thereof, a pharmaceutically acceptable salt, or a prodrug or pharmaceutically active metabolite can be combined or separate with the prior drug use for preparation for the treatment of epidermal growth factor receptor signal transferred to the maladjustment of the related disease, wherein the epidermal growth factor receptor as HER - 1, HER - 2, HER - 3 or HER - 4, wherein the epidermal growth factor receptor signal transferred to the maladjustment of the related disease is a non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder and cervical squamous cell carcinoma. (by machine translation)

Thiophenothiazolacyl piperazine compound and medical use thereof

The invention belongs to the technical field of medicines, and relates to a thiophenothiazolacyl piperazine compound and a preparation method thereof as well as application of the thiophenothiazolacylpiperazine compound as an epidermal growth factor receptor tyrosine kinase inhibitor. The compound, a precursor drug thereof, an active metabolite of the drug and pharmaceutically acceptable salt are as shown in the formula (I), wherein R is independently selected from hydrogen and methyl; R' is independently selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl, cyan, halogen, amino, nitryl, trifluoromethyl or trifluoromethoxy.

1-(thieno[2,3-b] thiapyran formyl-4-aliphatic piperazine compound and medicinal application thereof

The invention belongs to the technical field of medicines and relates to a 1-(thieno[2,3-b] thiapyran formyl-4-aliphatic piperazine compound and medicinal application thereof. The compound is of a structure as shown in the specification, in the formula, R is independently selected from hydrogen and methyl; R' is independently selected from methyl, benzyl, benzhydryl and (4-chlorphenyl) (phenyl) methyl. The 1-(thieno[2,3-b] thiapyran formyl-4-aliphatic piperazine compound provided by the invention and a stereisomer, a pharmaceutically acceptable salt, a precursor medicine or a medicine active metabolite thereof can be combined with a conventional medicine or are independently used to prepare medicines for related diseases such as epidermal growth factor receptor signal transferring disorder, an epidermal growth factor receptor is HER-1, HER-2, HER-3 or HER-4, the related diseases such as epidermal growth factor receptor signal transferring disorder are non-small cell lung cancer, stomach cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer and head and neck squamous cell carcinoma.

4-hydroximino thieno[2,3-b] thiapyran-2-formamide compound and application thereof

The invention belongs to the technical field of medicines and relates to a 4-hydroximino thieno[2,3-b] thiapyran-2-formamide compound and medicinal application thereof. The 4-hydroximino thieno[2,3-b]thiapyran-2-formamide compound is of a structure as shown in the specification, in the formula, R', R'' and R''' are independently selected from hydrogen and phenyl, C1-C6 alkyl substituted phenyl,C1-C6 alkoxy substituted phenyl, halogen substituted phenyl, halogen C1-C6 alkoxy substituted phenyl and substituted C1-C6 alkyl; phenyl or morpholinyl is adopted as a substituent group, or R' and R''and N atoms connected with R' and R'' form the morpholinyl or piperidyl. The 4-hydroximino thieno[2,3-b] thiapyran-2-formamide compound provided by the invention and a stereisomer, a pharmaceuticallyacceptable salt, a precursor medicine or a medicine active metabolite thereof can be combined with a conventional medicine or are independently used to prepare medicines for related diseases such asepidermal growth factor receptor signal transferring disorder.

Thiophene and benzopyran pyrazole compound and its medical use

The invention belongs to the field of medical technologies, and relates to a thieno-thiopyrano pyrazole compound and pharmaceutical applications thereof. The thieno-thiopyrano pyrazole compound comprises derivatives of the thieno-thiopyrano pyrazole compound and pharmaceutical applicable salts. The thieno-thiopyrano pyrazole compound and salts added by pharmaceutically applicable acids of the compound can be combined with existing drugs or used alone as a lipoxygenase inhibitor, and used for treating related diseases such as chronic dull pains including inflammations, gout, headache, toothache, neuralgia and arthralgia which are relevant to an arachidonic acid metabolizing process.

Thiopheneglyoxylic and sulfur miscellaneous compound and use thereof

The invention belongs to the technical field of medicines and relates to a thienothio compound and an application thereof. A thienothiapyran compound comprises derivatives and pharmaceutically applicable salt of the thienothiapyran compound, and has a str

Identification of 1, 4-Dihydrothieno[3', 2':5, 6]thiopyrano [4, 3-c]pyrazole derivatives as human 5-lipooxygenase inhibitors

A series of novel 1,4-dihydrothieno[3',2':5,6]thiopyrano [4,3-c]-pyrazole-3-carboxamide derivatives were synthesized and evaluated for their inhibitory activity to human 5-lipo-oxygenase (5-LOX). Compound 7c was found to exhibit significant inhibition to human 5-LOX with IC50 value of 5.7 ± 0.9 μM. Compound 7c was further studied using molecular docking in order to delineate its structure-activity relationship and to gain insight into the design of effective 5-LOX inhibitors.

Development of thieno[3',2':5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the estrogen receptor ligands: Synthesis, characterization and biological activity

Estrogen receptors (ERs) are members of a superfamily of ligand-modulated nuclear receptors, which have been associated with an increased risk of cardiovascular diseases and breast cancer. Based on molecular docking studies, 1,4-dihydrothieno[3',2':5,6]th